- Abstract Submission Deadline: Monday, October 4, 2021
- Abstract Accept/Reject Notification: End of November 2021
- Late Breaking Abstract Submissions: November 22 - December 6, 2021
- Final Oral Abstract Slides Upload: April 8, 2022
- Digital Poster Upload Deadline: April 15, 2022
Work submitted for presentation should not have been reported previously in an archival scientific publication, either as an article or as an abstract, at the time of submission. Data that has been, or will be, presented at any other meeting before being presented at the 2022 Tandem Meetings of ASTCT and CIBMTR, will not be accepted for presentation.
Due to the overlap in abstract submission and notification timelines for the 2021 ASH Annual Meeting, data submitted to the 2021 ASH Annual Meeting is acceptable for submission to the 2022 Tandem Meetings of ASTCT and CIBMTR. Please note that the Tandem Meetings Scientific Organizing Committee has final say on whether an abstract presented at the 2021 ASH Meeting will be eligible for presentation at the 2022 Tandem Meetings.
Conference Registration FeeAbstract presenting authors will be eligible for the Early Registration Rate even after Standard and On-Site registration rates apply.
Abstract Submission Fee
There is a $50 non-refundable abstract submission fee.
Abstract Categories
Abstract data/research must apply to one of the following categories:
- Acute and chronic leukemia (AML, MDS, MPD ALL, CML, CLL) - Basic/preclinical
- Acute and chronic leukemia (AML, MDS, MPD ALL, CML, CLL) - Clinical
- Acute Regimen-Related Toxicity and Supportive Care
- CAR-T - Basic: Antigen Finding, Safety, Effector Cells
- CAR-T - Clinical: Regulatory, Efficacy, Persistence
- Cellular and Gene therapy: Basic/preclinical
- Cellular and Gene therapy: Clinical, processing
- Conditioning regimens
- Donor Health and Safety
- Graft Sources (related, matched and mismatched unrelated, haplo, autologous, cord blood, bone marrow and peripheral blood)
- Graft-versus-Host and graft versus tumor - Basic/preclinical
- Graft-versus-Host and graft versus tumor - Clinical: Prevention, treatment and biomarkers
- Health Services
- Hematopoietic stem cell niche, biology, expansion
- Hemoglobinopathies, Primary Immune deficiencies and Inborn Errors of Metabolism - Basic/preclinical
- Hemoglobinopathies, Primary Immune deficiencies and Inborn Errors of Metabolism - Clinical
- HSCT for autoimmune disorders
- HSCT, gene and other cellular therapies in countries with constrained resources
- Immune reconstitution and Immunobiology
- Immunogenetics
- Infectious Diseases and Cytotoxic T lymphocytes
- IT and Informatics for Transplant and Cellular Therapy (CIBMTR)
- Late Effects and Quality of Life
- Lymphoma/myeloma - Basic/preclinical
- Lymphoma/myeloma - Clinical
- Marrow failure syndromes (congenital and acquired)
- Advanced Practice Professionals (for Advance Practice Provider Track)
- Relapse - Basic/preclinical
- Relapse - Clinical: Prevention and Treatment
- Quality and Transplant Program Administration (for Administrative Director Track)
- Study design and statistics
- Transplant and Cell Therapy for Aged and Geriatric Populations
- Transplantation Data Management (for Clinical Research Professionals/Data Managers Track)
- Transplantation Pharmacology (for Pharmacists Track)
- Administration
- Clinical
- Education
- Research
The first author listed for each abstract serves as the Presenting Author and is the primary contact for all correspondence regarding the abstract.
The Presenting Author is responsible for the following:
- Ensuring that all authors have read the abstract and agreed to be co-authors.
- Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the Tandem Meetings of ASTCT and CIBMTR.
- Obtaining all of the conflict-of-interest disclosure information from co-authors.
- Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers are able to focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar, or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission.
- Ensuring that they will be prepared to present and to respond to questions regarding the abstract. If that is not the case, the authors should choose a poster as their preference.
Each abstract author agrees and certifies that they:
- Have read all of the rules and agrees to be bound by them.
- Are responsible for submission of the abstract in accordance with the rules, and waives any and all claims against ASTCT/CIBMTR/Tandem Meetings of ASTCT and CIBMTR and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
Abstract Review
Abstracts are peer reviewed on their scientific merits and according to subject category. Individuals submitting abstracts must indicate the appropriate review category. Abstracts may be re-categorized to a more appropriate category based on guidance from the Tandem Meetings Co-Chairs. The ASTCT, CIBMTR and Tandem Meetings of ASTCT and CIBMTR reserve the right to make minor editorial grammatical/spelling changes if required for clarity of presentation..
Abstract Corrections
All changes/edits to submitted abstracts are strictly the responsibility of the first author and must be conducted within the confines of the abstract submission portal. Requests for assistance in accessing abstracts to allow for modifications, should be submitted in writing to tandemabstracts@astct.org.
Abstract Withdrawals
Abstract withdrawals can be made within the submission system by the first author, no later than Friday, October 29, 2021 pm PT.
Abstract withdrawal requests after Friday, October 29, 2021 pm PT must be made, in writing only, to tandemabstracts@astct.org. ASTCT and CIBMTR Staff cannot fulfill any withdrawal requests by phone. Accepted abstracts that remain in the submission system on November 16, 2021 may be published online and in ASTCT's journal, Transplantation and Cellular Therapy, as submitted.
Incomplete Abstracts
Any submitted abstract deemed incomplete within the submission system on October 5, 2021 at 12:01 am PT will be eliminated without further notification prior to abstracts being distributed to the 2022 Tandem Meetings abstract review team.
Late-Breaking Abstracts
The submission of late-breaking abstracts will be allowed from November 22, 2021 – December 6, 2021 at 11:59 pm PT.
Late-breaking abstract authors must complete a request for information to explain the need for submission during the late-breaking abstract submission process, which will be shared with the abstract reviewers and program Co-Chairs.
Embargo
Abstracts submitted for presentation will be embargoed by the author(s) and the 2022 Tandem Meetings, upon submission.
Abstracts submitted for presentation to the 2022 Tandem Meetings will be embargoed by the author(s) and the 2022 Tandem Meetings, upon submission. The embargo will be lifted and abstracts will be made available for viewing on January 7, 2022 PT.
Copyright
Authors assign copyright of the abstract to ASTCT upon submission, unless one of the authors is a U.S. Federal employee. This means that the identical abstract may not be republished or submitted to another meeting; however, Elsevier may grant permission for reuse of abstract content on behalf of ASTCT. You can request to re-use an abstract by clicking here.
|
Need Assistance?
|
|
Registration: TandemRegistration@conferencedirect.com
Housing: TandemHousing@conferencedirect.com
|
|
Abstract Questions: TandemAbstracts@astct.org
|
 |
